Results 251 to 260 of about 355,709 (346)

Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review. [PDF]

Oncol Res
Kokkotou E, Charpidou A, Syrigos N.
europepmc   +1 more source

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

Adjuvant Chemotherapy Aids Survival in NSCLC

, 2003
Michael Smith
openalex   +1 more source

RHBDD1 induces cell cycle arrest in TP53-mutant NSCLC cells by promoting endoplasmic reticulum-associated degradation of p53 and DNA-PKcs. [PDF]

Eur J Med Res
Chen Y, Wang Y, Shen S, Zhang L, Liu J, Yan X, Peng H, Xu Z.   +7 more
europepmc   +1 more source

Rad51 at the Crossroads: Bridging DNA Repair, Tumorigenesis, and Immune Regulation

Med Research, EarlyView.
Therapeutic landscape of Rad51 in cancer treatment. Key elements include (1) DNA damage sources (PARPi, chemo/radiotherapy); (2) repair pathways (Rad51‐mediated HR); (3) intervention strategies (Rad51 inhibitors, CRISPR/Cas9); and (4) combination approaches (immunotherapy). The figure is created with BioRender.com.
Zhendong Qin, Mingjun Lu, Jingwei Guo, Chenyang Wang, Teng Ma   +4 more
wiley   +1 more source

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Cancer immunology research, 2017
P. Tumeh, M. Hellmann, O. Hamid, K. Tsai, K. Loo, M. Gubens, M. Rosenblum, C. Harview, J. Taube, N. Handley, N. Khurana, Adi Nosrati, M. Krummel, Andrew Tucker, E. Sosa, P. J. Sanchez, N. Banayan, J. C. Osorio, D. L. Nguyen-Kim, Jeremy Chang, I. Shintaku, P. Boasberg, E. Taylor, P. Munster, A. Algazi, B. Chmielowski, R. Dummer, T. Grogan, D. Elashoff, Jimmy Hwang, S. Goldinger, E. Garon, R. Pierce, A. Daud   +33 more
semanticscholar   +1 more source

ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer. [PDF]

J Immunother Cancer
Wen S, Du X, Zhu M, Huang C, Lin Z, Li M, Hu B, Wang X, Jiang F, Zhou G, Zhu W, Yu G, Xu C, Shen B.   +13 more
europepmc   +1 more source

A case-controlled study comparing sleeve lobectomy and standard lobectomy of NSCLC

, 2003
Masahiko Harada, Michael K.Y. Hsin, George Ladas, Peter Goldstraw, Michael Dusmet   +4 more
openalex   +2 more sources

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Annals of Oncology, 2018
J. Remon, C. Steuer, S. Ramalingam, E. Felip   +3 more
semanticscholar   +1 more source

PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC. [PDF]

J Biomed Sci
Hsu CC, Huang DD, Hsu WH, Hsieh MS, Lin FY, Tai PC, Chou SY, Tsai HH, Tseng CY, Liao BC, Shih JY, Yang JC.   +11 more
europepmc   +1 more source